IRD vs JANX

For growth investors, Janux Therapeutics, Inc.

(JANX) is the stronger pick with -5. 6% revenue growth year-over-year, versus -42. 3% for Opus Genetics, Inc. (IRD). Analysts rate Opus Genetics, Inc. (IRD) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Opus Genetics, Inc.

(IRD) delivered a total return of +315. 5%, compared to -42. 2% for Janux Therapeutics, Inc. (JANX). Over 10 years, the gap is even starker: IRD returned +315. 5% versus JANX's -42. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Opus Genetics, Inc.

(IRD) is the lower-risk stock at 1. 13β versus Janux Therapeutics, Inc. 's 1. 45β — meaning JANX is approximately 29% more volatile than IRD relative to the S&P 500.

By revenue growth (latest reported year), Janux Therapeutics, Inc.

(JANX) is pulling ahead at -5. 6% versus -42. 3% for Opus Genetics, Inc. (IRD). On earnings-per-share growth, the picture is similar: Janux Therapeutics, Inc. grew EPS -43. 0% year-over-year, compared to -367. 4% for Opus Genetics, Inc.. Over a 3-year CAGR, IRD leads at 165. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Opus Genetics, Inc.

(IRD) is the more profitable company, earning -523. 4% net margin versus -1576. 7% for Janux Therapeutics, Inc. — meaning it keeps -523. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IRD leads at -564. 7% versus -1576. 7% for JANX. At the gross margin level — before operating expenses — IRD leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Opus Genetics, Inc.

(IRD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13), +315. 5% 10Y return). Both have compounded well over 10 years (IRD: +315. 5%, JANX: -42. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.